Clinical trial
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
Active, not recruiting · Phase 3 · 5 countries · Registry ID NCT06972472
Active, not recruitingPhase 3Interventional
What this study is about
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity, Overweight, Type 2 Diabetes
Full registry criteria
Inclusion Criteria: * Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening * Have type 2 diabetes * Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening * Have a history of at least one unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have type 1 diabetes * Have an unstable body weight within 90 days prior to screening * Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening * Have acute or chronic hepatitis or pancreatitis * Are taking other medications or alternative remedies to manage weight loss
Treatments and study arms
Orforglipron
Drug
Administered orally
Placebo
Drug
Administered orally
Primary outcomes
Change from Baseline in Hemoglobin A1c (HbA1c)Baseline, Week 40
Study locations
80 locations were listed when this page was built. The first 40 are shown.
CARE - Centro de Alergia y Enfermedades Respiratorias🇦🇷 Buenos Aires, Argentina
CIPREC🇦🇷 Buenos Aires, Argentina
Centro Médico Viamonte🇦🇷 Buenos Aires, Argentina
Instituto Centenario🇦🇷 CABA, Argentina
Instituto Médico Catamarca IMEC🇦🇷 Rosario, Argentina
Centro de Diagnóstico y Rehabilitación (CEDIR)🇦🇷 Santa Fe, Argentina
Peking University Third Hospital🇨🇳 Beijing, China
Xuanwu Hospital Capital Medical University🇨🇳 Beijing, China
Sichuan Provincial People's Hospital🇨🇳 Chengdu, China
The Second Affiliated Hospital Chongqing Medical University🇨🇳 Chongqing, China
Zhujiang Hospital🇨🇳 Guangzhou, China
The Fourth Affiliated Hospital of Harbin Medical University🇨🇳 Harbin, China
The Second People's Hospital of Hefei🇨🇳 Hefei, China
Jinan Central Hospital🇨🇳 Jinan, China
The First Affiliated Hospital of Henan University of Science &Technology🇨🇳 Luoyang Shi, China
The Second Affiliated Hospital of Nanjing Medical University🇨🇳 Nanjing, China
Zhongda Hospital Southeast University🇨🇳 Nanjing, China
The Second Hospital of Tianjin Medical University🇨🇳 Tianjin, China
Donmed s.r.o.🇨🇿 Ostrava, Czechia
Milan Kvapil s.r.o., Diabetologicka ambulance🇨🇿 Prague, Czechia
Medical Plus🇨🇿 Uherské Hradiště, Czechia
MUDr. Alena Vachova🇨🇿 České Budějovice, Czechia
Nemocnice Cesky Krumlov🇨🇿 Český Krumlov, Czechia
InnoDiab Forschung Gmbh🇩🇪 Essen, Germany
Medizentrum Essen Borbeck🇩🇪 Essen, Germany
Diabetes Zentrum Wilhelmsburg🇩🇪 Hamburg, Germany
AmBeNet GmbH🇩🇪 Leipzig, Germany
Gemeinschaftspraxis Dr. Taeschner/Dr. Bonigut🇩🇪 Leipzig, Germany
Medicover Neuroendokrinologie🇩🇪 Munich, Germany
RED-Institut GmbH🇩🇪 Oldenburg, Germany
Hasegawa Medicine Clinic🇯🇵 Chitose, Japan
Fukuwa Clinic🇯🇵 Chūōku, Japan
The Institute of Medical Science, Asahi Life Foundation🇯🇵 Chūōku, Japan
Tokyo-Eki Center-building Clinic🇯🇵 Chūōku, Japan
Tokuyama Clinic🇯🇵 Mihama-ku,Chiba City, Japan
Medical Corporation Heishinkai ToCROM Clinic🇯🇵 Shinjuku-ku, Japan
Medical Corporation Heishinkai OCROM Clinic🇯🇵 Suita-shi, Japan
Olive Takamatsu Medical Clinic🇯🇵 Takamatsu, Japan
Shimokitazawa Tomo Clinic🇯🇵 Tokyo, Japan
Tsuchiura Medical & Health Care Center🇯🇵 Tsuchiura, Japan